Literature DB >> 26283695

Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.

Markus Kraemer1, Ralph Weber2, Michèle Herold2, Peter Berlit2.   

Abstract

Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by acute thunderclap headache, evidence of vasoconstriction in conventional angiography or magnetic resonance angiography and reversibility of these phenomena within 12 weeks. Some triggering factors, for example drugs such as selective serotonin reuptake inhibitors, sumatriptan, tacrolimus, cyclophosphamide and cocaine, or states such as pregnancy, puerperium or migraine have been described. We describe the case of a 29-year-old woman with RCVS associated with fingolimod three months after childbirth. This case represents the first report of RCVS in fingolimod treatment.
© The Author(s), 2015.

Entities:  

Keywords:  Reversible cerebral vasoconstriction syndrome; fingolimod; trigger

Mesh:

Substances:

Year:  2015        PMID: 26283695     DOI: 10.1177/1352458515600249

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

Review 1.  Heritable and non-heritable uncommon causes of stroke.

Authors:  A Bersano; M Kraemer; A Burlina; M Mancuso; J Finsterer; S Sacco; C Salvarani; L Caputi; H Chabriat; S Lesnik Oberstein; A Federico; E Tournier Lasserve; D Hunt; M Dichgans; M Arnold; S Debette; H S Markus
Journal:  J Neurol       Date:  2020-04-21       Impact factor: 4.849

Review 2.  An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis.

Authors:  Caila Vaughn; Aisha Bushra; Channa Kolb; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

3.  Systemic Sclerosis, Reversible Cerebral Vasoconstriction Syndrome, and NeuroMyelitis Optica in a Patient.

Authors:  Masoud Etemadifar; Mehdi Shafiei; Mehri Salari; Ali Modares Sadeghi; Mohammad Fakhrolmobasheri
Journal:  Case Reports Immunol       Date:  2022-07-12

4.  Cerebrospinal fluid findings in reversible cerebral vasoconstriction syndrome: a way to differentiate from cerebral vasculitis?

Authors:  L Kraayvanger; P Berlit; P Albrecht; H-P Hartung; M Kraemer
Journal:  Clin Exp Immunol       Date:  2018-07-23       Impact factor: 4.330

Review 5.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11

6.  Insights into Initial Demyelinating Episodes of Central Nervous System during Puerperium.

Authors:  Qian Wu; Bo Chen; Na Liu; Yang Hu; Chao Pan; Ping Zhang; Zhou-Ping Tang; Bi-Tao Bu
Journal:  Chin Med J (Engl)       Date:  2017-08-05       Impact factor: 2.628

Review 7.  Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.

Authors:  Ramón Villaverde-González
Journal:  Degener Neurol Neuromuscul Dis       Date:  2022-01-05

8.  Intra-arterial application of nimodipine in reversible cerebral vasoconstriction syndrome: a neuroradiological method to help differentiate from primary central nervous system vasculitis.

Authors:  Daniel Strunk; Roland Veltkamp; Sven G Meuth; René Chapot; Markus Kraemer
Journal:  Neurol Res Pract       Date:  2022-02-28

9.  Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.

Authors:  Rozita Doosti; Abdorreza Naser Moghadasi; Amir Reza Azimi; Shahrokh Karbalai Saleh; Masoud Etemadifar; Vahid Shaygannejad; Fereshteh Ashtari; Mohammad Hossein Harirchian; Seyed Bahaadin Siroos; Hormoz Ayramloo; Nastaran Majdinasab; Seyyed Mohammad Masood Hojjati; Nabiollah Asghari; Seyed Mohammad Baghbanian; Hamed Cheraghmakani; Mahmoud Abedini; Behnaz Sedighi; Negar Mohseni Abbas Abadi; Maedeh Ghasemitabar; Sara Talebianpour; Tohid Babayi Daylari; Vahid Dana; Neda Ghaleh Noie; Mohammad Ali Sahraian
Journal:  Caspian J Intern Med       Date:  2021-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.